Login to Your Account


Diabetes deal sweet for BMS; $2.7B in Astrazeneca JV exit

By Randy Osborne
Staff Writer

Thursday, December 19, 2013
The ongoing effort by Bristol-Myers Squibb Co. (BMS) to become a specialty biopharma firm led to its $2.7 billion split from the joint venture for Type II diabetes with Astrazeneca plc, leaving investors in both firms to sort through details.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription